# Enabling Next-Generation AI in Autoimmune R&D

Autoimmune diseases are dynamic, varied, and difficult to characterize using traditional clinical visits and static datasets. As drug developers rely on AI and biomarker-driven approaches to understand disease activity and therapeutic response, they face a fundamental limitation: most available data offers only isolated snapshots in time, missing the dynamic transitions that truly define immune-mediated conditions.

In this discussion, our speakers will explore how longitudinal, temporally relevant, multimodal data collected through direct connections with individuals can help unlock new opportunities across early R&D for immune-mediated diseases. Attendees will gain insights on how these data can be used to sharpen R&D confidence in early-phase programs and support AI-driven innovation in autoimmune drug development.

- Learn how to redesign your autoimmune data strategy by identifying gaps in current data sets and determining where continuous data collection can strengthen biomarkers and translational efforts.
- Apply real-world and molecular signals to detect early flare signatures and characterize transitions between disease states.
- Integrate longitudinal evidence into biomarker development decisions.
- Strengthen translational and early development strategy with time-based patterns in immune activity data.

[**Watch the webinar here**](https://www.fiercepharma.com/premium/webinar/1375566)

## Related work

### [Evidation Launches Temporal Proteomics Platform to Power Autoimmune Research](/content/resources/evidation-launches-temporal-proteomics-platform-and-autoimmune-cohort/index.html)  
January 8, 2026

### [Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals](/content/resources/real-world-glp-1-dosing-behaviors/index.html)  
December 16, 2025

### [Evidation Appoints Dr. Ghazanfar Khan as Chief Medical Officer](/content/resources/evidation-appoints-dr-ghazanfar-khan-as-chief-medical-officer/index.html)  
December 2, 2025

## Have questions?

[CONTACT US](/content/for-customers/contact-us/index.html)